AI Tokens
Stock Analysis on Net

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

Thermo Fisher Scientific Inc., common-size consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

Microsoft Excel
Sep 26, 2026 Jun 27, 2026 Mar 28, 2026 Dec 31, 2025 Sep 27, 2025 Jun 28, 2025 Mar 29, 2025 Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022 Dec 31, 2021 Oct 2, 2021 Jul 3, 2021 Apr 3, 2021
Short-term obligations and current maturities of long-term obligations 1.98 2.98 2.73 3.20 3.71 2.19 2.85 2.27 4.10 5.20 4.58 3.66 4.94 5.12 6.47 5.74 1.12 1.12 2.01 2.67 0.03 0.01 0.01
Accounts payable 2.70 2.89 2.95 3.28 3.03 2.94 3.08 3.16 2.60 2.59 2.63 2.91 2.58 2.57 2.96 3.48 2.73 2.85 2.88 3.01 3.13 3.10 3.25
Accrued payroll and employee benefits 1.81 1.50 1.38 1.81 1.83 1.50 1.43 2.04 1.82 1.52 1.35 1.62 1.50 1.39 1.38 2.16 2.06 1.90 1.76 2.55 2.47 2.20 1.99
Contract liabilities 2.57 2.58 2.58 2.46 2.77 2.77 2.89 2.93 2.65 2.63 2.71 2.72 2.62 2.75 2.81 2.68 2.84 3.01 3.10 2.79 1.96 2.17 2.12
Other accrued expenses 3.34 3.38 3.26 3.02 3.11 3.16 3.05 3.29 3.38 3.06 3.07 3.29 2.93 3.16 3.16 3.45 3.54 3.26 3.27 3.10 2.96 2.75 3.24
Current liabilities 12.40% 13.31% 12.91% 13.77% 14.45% 12.56% 13.30% 13.70% 14.55% 15.00% 14.35% 14.19% 14.59% 15.00% 16.78% 17.51% 12.28% 12.14% 13.01% 14.12% 10.53% 10.23% 10.61%
Deferred income taxes 1.29 1.40 1.86 1.35 0.82 0.62 1.05 1.30 1.12 1.54 1.87 1.95 2.70 3.02 3.14 2.93 3.47 3.67 3.77 4.03 1.99 2.41 2.86
Other long-term liabilities 4.02 4.01 3.90 3.87 4.15 4.22 4.01 4.10 4.33 4.46 4.70 4.70 4.46 4.30 4.47 4.36 4.86 5.01 5.03 4.77 5.41 5.19 5.08
Long-term obligations, excluding current maturities 34.24 34.62 35.37 32.49 30.92 32.61 31.67 29.86 31.08 30.75 32.09 31.71 31.41 31.02 30.78 29.76 31.09 32.29 33.84 33.99 29.47 27.73 28.27
Long-term liabilities 39.54% 40.03% 41.14% 37.72% 35.89% 37.45% 36.73% 35.26% 36.53% 36.74% 38.66% 38.36% 38.57% 38.34% 38.39% 37.05% 39.42% 40.97% 42.64% 42.80% 36.87% 35.33% 36.22%
Total liabilities 51.94% 53.34% 54.04% 51.48% 50.35% 50.01% 50.04% 48.96% 51.08% 51.74% 53.01% 52.55% 53.16% 53.33% 55.17% 54.56% 51.70% 53.11% 55.65% 56.92% 47.40% 45.56% 46.83%
Redeemable noncontrolling interest 0.11 0.11 0.11 0.11 0.13 0.12 0.13 0.12 0.13 0.12 0.12 0.12 0.12 0.12 0.13 0.12 0.13 0.13 0.12 0.13 0.00 0.00 0.00
Preferred stock, $100 par value; none issued 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Common stock, $1 par value 0.39 0.39 0.39 0.40 0.43 0.44 0.45 0.46 0.44 0.45 0.46 0.45 0.46 0.47 0.47 0.45 0.49 0.49 0.47 0.46 0.60 0.65 0.66
Capital in excess of par value 16.85 16.67 16.52 16.82 17.79 18.01 18.29 18.46 17.77 17.92 18.01 17.51 17.69 18.10 17.84 17.23 18.33 18.18 17.57 17.00 21.68 23.38 23.79
Retained earnings 55.80 54.95 53.52 53.61 55.67 55.22 54.97 54.56 51.23 50.70 49.99 47.98 47.26 47.06 45.49 43.14 44.68 43.14 40.46 37.25 46.03 47.38 46.03
Treasury stock at cost -23.12 -23.30 -22.39 -20.22 -21.66 -21.01 -21.47 -19.76 -18.16 -18.46 -18.73 -15.33 -15.58 -16.03 -15.93 -12.37 -12.16 -12.10 -11.82 -9.38 -12.11 -13.08 -13.43
Accumulated other comprehensive loss -1.98 -2.17 -2.20 -2.22 -2.72 -2.76 -2.37 -2.77 -2.47 -2.45 -2.85 -3.27 -3.12 -3.11 -3.23 -3.19 -3.23 -3.01 -2.53 -2.45 -3.61 -3.88 -3.89
Total Thermo Fisher Scientific Inc. shareholders’ equity 47.94% 46.55% 45.85% 48.40% 49.52% 49.90% 49.87% 50.95% 48.81% 48.16% 46.88% 47.34% 46.70% 46.49% 44.64% 45.27% 48.10% 46.69% 44.16% 42.88% 52.60% 54.44% 53.17%
Noncontrolling interests 0.01 0.01 0.01 0.01 0.01 -0.04 -0.03 -0.03 -0.02 -0.01 -0.01 -0.01 0.02 0.05 0.06 0.06 0.07 0.07 0.07 0.07 0.00 0.00 0.00
Total equity 47.94% 46.55% 45.85% 48.41% 49.53% 49.86% 49.83% 50.92% 48.79% 48.14% 46.87% 47.33% 46.72% 46.55% 44.70% 45.32% 48.17% 46.76% 44.23% 42.95% 52.60% 54.44% 53.17%
Total liabilities, redeemable noncontrolling interest and equity 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%

Based on: 10-Q (reporting date: 2026-09-26), 10-Q (reporting date: 2026-06-27), 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-02), 10-Q (reporting date: 2021-07-03), 10-Q (reporting date: 2021-04-03).


The capital structure of the organization exhibits a dynamic balance between total liabilities and total equity over the analyzed period. Total liabilities experienced a notable increase, peaking at 56.92% in December 2021, before stabilizing within a range of 48.96% to 54.04% through September 2026. Conversely, total equity fluctuated inversely, starting at 53.17% in April 2021, dipping to a low of 42.88% in December 2021, and subsequently recovering to end the period at 47.94%.

Liability Composition and Debt Trends
Long-term obligations, excluding current maturities, constitute the most significant portion of total liabilities. This component showed a general upward trend, rising from 28.27% in April 2021 to a peak of 35.37% in March 2026, indicating a strategic reliance on long-term debt financing. Current liabilities remained relatively stable, generally fluctuating between 10% and 17% of the total capital structure, with a peak of 17.51% in December 2022. Within the current liability framework, accounts payable and other accrued expenses remained consistent, typically representing between 2.5% and 3.5% each.
A steady decline is observed in deferred income taxes, which decreased from 2.86% in April 2021 to 1.29% by September 2026, suggesting a reduction in the relative weight of temporary timing differences between accounting and tax reporting.
Equity Dynamics and Capital Allocation
Retained earnings demonstrate a strong and consistent upward trajectory, growing from 46.03% in April 2021 to 55.80% by September 2026, despite a sharp temporary decline in December 2021. This growth indicates a sustained capacity to accumulate earnings over time.
A significant increase in treasury stock at cost is observed, moving from -13.43% in April 2021 to -23.12% in September 2026. The expansion of this contra-equity account suggests an aggressive and sustained program of share repurchases, which has partially offset the growth in retained earnings in terms of total equity percentage.
Capital in excess of par value showed a gradual downward trend, decreasing from 23.79% in April 2021 to 16.85% in September 2026, reflecting a shift in the relative composition of shareholders' equity toward accumulated earnings rather than contributed capital.

Overall, the financial position is characterized by a transition toward higher long-term leverage and a simultaneous commitment to returning capital to shareholders via buybacks, while maintaining a strong core of retained earnings to support the balance sheet.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?